Effect of PCI combined with rosuvastatin therapy on endothelial function in patients with acute myocardialinfarction
PCI联合瑞舒伐他汀对急性心肌梗死患者的临床疗效及对内皮功能的影响

摘要

目的 分析经皮冠状动脉介入（Percutaneous coronary intervention，PCI）联合瑞舒伐他汀对急性心肌梗死患者的临床疗效及对内皮功能的影响。方法 于2020年6月-2021年6月在我院进行PCI联合瑞舒伐他汀治疗的84例急性心肌梗死患者，按照抽签法将患者分为PCI组与联合组各42例。PCI组采用PCI术进行治疗，联合组先进行瑞舒伐他汀治疗再采用PCI术进行治疗。对两组生化指标[超敏-C反应蛋白（High sensitivity C-reactive protein；hs-CRP）、基质金属蛋白酶9（Matrix metalloproteinase 9；MMP-9）、脑钠肽（brain natriuretic peptide；BNP）]、内皮功能、室壁运动积分指数（Chamber wall motion integral index，WMSI）指标、TIMI血流分级、并发症发生率、1、3、6个月死亡率、治疗效果进行统计，并进行比较。结果 治疗后联合组生化指标显著改善（P＜0.05）；治疗后联合组内皮功能及WMSI指标较低（P＜0.05）；治疗后联合组0-Ⅱ级占比较低，Ⅲ级较高（P＜0.05）；联合组并发症发生率明显降低（P＜0.05）；联合组1个月死亡率降低无差异（P＞0.05）；联合组3、6个月死亡率降低（P＜0.05）；联合组治疗总有效率明显更高（P＜0.05）。结论 PCI联合瑞舒伐他汀有效改善急性心肌梗死患者对急性心梗死患者的生化指标及内皮功能，降低患者的死亡率，其疗效显著，值得临床推广。

Abstract

Objective To analyze the clinical efficacy of percutaneous coronary intervention (PCI) combined with rosuvastatin in patients with acute myocardial infarction and its effect on endothelial function.
Methods: From June 2020 to June 2021, 84 patients with acute myocardial infarction who were treated with PCI and rosuvastatin in our hospital were divided into PCI group and combined group, 42 patients in each group. The PCI group was treated with PCI, and the combined group was treated with rosuvastatin and then PCI. Statistics were made on biochemical indicators [High sensitivity C-reactive protein; hs CRP; Matrix metalloproteinase 9; MMP-9; brain natriuretic peptide; BNP], endothelial function, chamber wall motion integral index (WMSI), TIMI blood flow classification, incidence of complications, mortality in 1, 3 and 6 months, and treatment effect, And compare them.
Results: After treatment, the biochemical indexes in the combined group were significantly improved (P<0.05); After treatment, the endothelial function and WMSI indexes in the combined group were lower (P<0.05); After treatment, the proportion of grade 0 - Ⅱ in the combined group was relatively low, while grade Ⅲ was relatively high (P<0.05); The incidence of complications in the combined group was significantly lower (P<0.05); There was no difference in the 1-month mortality reduction in the combined group (P>0.05); The mortality of the combined group at 3 and 6 months decreased (P<0.05); The total effective rate of the combined group was significantly higher (P<0.05).
Conclusion  : PCI combined with rosuvastatin can effectively improve the biochemical indicators and endothelial function of patients with acute myocardial infarction and reduce the mortality of patients with acute myocardial infarction. It has a significant effect and is worthy of clinical promotion.